PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Biocompatibles UK Ltd / BTG Plc

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

BTG Receives Health Canada Approval for DC Bead LUMI™ - First commercially available radiopaque drug-eluting bead in Canada that provides real-time visible confirmation of bead location during embolization for the treatment of tumours in patients with HCC and mCRC - BTGplc.com
BTG Receives Health Canada Approval for DC Bead LUMI™

 

NewswireToday - /newswire/ - Ottawa, Québec, Canada, 2016/08/25 - First commercially available radiopaque drug-eluting bead in Canada that provides real-time visible confirmation of bead location during embolization for the treatment of tumours in patients with HCC and mCRC - BTGplc.com. LSE: BTG

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

BTG International Canada, Inc., part of the global specialist healthcare company BTG, today announced that it has received approval from Health Canada for DC Bead LUMI™, the first commercially available radiopaque drug-eluting bead that can be loaded with doxorubicin or irinotecan for the local treatment of tumours in patients with hepatocellular carcinoma (HCC) and malignant colorectal cancer metastasized to the liver (mCRC).1

DC Bead LUMI™ is a next generation development of DC Bead® that enables real-time visible confirmation of bead location during embolization. This innovative new technology has the potential to provide interventional radiologists increased control, enabling real-time adjustments to optimize patient treatment. The lasting radiopacity of DC Bead LUMI™ also means it will also be visible in follow-up scans, allowing precise evaluation of the completeness of tumour treatment.2

Brad Pearson, Director, Commercial Operations at BTG International Canada Inc., commented: “DC Bead LUMI™ reinforces our leadership in embolization technology and our focus on bringing to market innovative products that better serve specialist physicians and their patients. We are excited by the potential to offer a new standard of care and look forward to providing DC Bead LUMI™ to Canadian physicians during the second half of 2016.”

BTG anticipates securing regulatory clearances for additional radiopaque bead products in other markets worldwide.

About BTG
BTG (btgplc.com) is a growing international specialist healthcare company bringing to market innovative products in specialist areas of medicine to better serve doctors and their patients. We have a portfolio of Interventional Medicine products to advance the treatment of liver tumours, severe blood clots, varicose veins and advanced emphysema, and Specialty Pharmaceuticals that help patients overexposed to certain medications or toxins. Inspired by patient and physician needs, BTG is investing to expand its portfolio to address some of today’s most complex healthcare challenges.

About BTG Interventional Medicine
BTG Interventional Medicine (btg-im.com) is part of BTG plc, a growing international specialist healthcare company. As medicine moves from major surgery to minor procedure, from the systemic to the local, no company endeavors to do more than BTG Interventional Medicine to help doctors in their quest to see more, reach further and treat smarter. Our growing portfolio of Interventional Medicine products is designed to advance the treatment of liver tumors, advanced emphysema, severe blood clots, and varicose veins.

Canadian Media Inquiries: Eileen Tobey, beSPEAK Communications Inc.
P: +1 416-540-4047 - E: Eileen[.]bespeakcommunications.com.

Investor Relations Inquiries: Andy Burrows, VP Corporate & Investor Relations
P: +44(0)20 7575 1741 / M: +44(0)79 9053 0605

References:
1. DC Bead LUMI™ Radiopaque Embolic Drug-Eluting Bead Canadian Instructions for Use V.1
2. Duran et al. Theranostics 6(1) 2016:28-39about BTG Interventional Medicine, please visit btg-im.com/.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Biocompatibles UK Ltd / BTG Plc

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


BTG Receives Health Canada Approval for DC Bead LUMI™

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

BTG | DC Bead LUMI™
Publisher Contact: Chris Sampson - BTGplc.com 
+44(0)20 7575 1595 / +44(0)7773 251178 (mobile) chris.sampson[.]btgplc.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Biocompatibles UK Ltd / BTG Plc securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Biocompatibles UK Ltd / BTG Plc / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Sub-Sahara Africa - Increase in Western Lifestyles Leads to Dire Need for Chronic Prescription Drugs Finds Frost & Sullivan
BD Initiates New Industry Alliance to Combat Rising Opioid Crisis
BTG and Society of Interventional Oncology to Explore Role of Minimally Invasive Therapies in Immuno-oncology
Ipsen to Acquire a Portfolio of Select Consumer Healthcare Products from Sanofi
BD Announces Early Access Program for BD Resolve™ Single-Cell Analysis Platform
Precision Medicine Unlocks the Future of Targeted Therapy in the Global Healthcare Industry Finds Frost & Sullivan
Sciformix Corporation Receives Prestigious 2017 Global Outsourcing Customer Service Leadership Award from Frost & Sullivan
Arven Pharmaceuticals Selects GE Healthcare’s FlexFactory to Improve Turkish and Regional Access to Biopharmaceuticals
Ipsen to Acquire Primary Care Platform in Italy from Akkadeas Pharma
Cost-Containment and Client-Centric Services Catalyse European Custom Procedure Trays and Packs Market Finds Frost & Sullivan
New BD Institute for Medication Management Excellence Aims to Improve Patient Safety and Outcomes through Collaboration
New Varicose Vein Treatment Offers Minimally Invasive Non Surgical Procedure to Canadians
Greenphire and Exostar Partner to Deliver Seamless, Secure Access to Clinical Research Site Payment Solution
PleurX™ Catheter System Receives FDA 510(k) Clearance for Specific Non-Malignant Recurrent Pleural Effusions
First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Al Rowaad Advocates & Legal Consultants

Visit  BizJobs.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)